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Chitosan Oligosaccharide Lactate Coated Hydroxyapatite 
Nanoparticles as a Vehicle for the Delivery of Steroid Drugs and 
the Targeting of Breast Cancer Cells  
Nenad L. Ignjatovića*, Marija Sakačb, Ivana Kuzminacb, Vesna Kojićc, Smilja Markovića, Dana 
Vasiljević-Radovićd, Victoria M. Wue, Vuk Uskokovićf and Dragan P. Uskokovića 
 
Low targeting efficiency and fast metabolism of antineoplastic drugs are hindrances to effective chemotherapies and there 
is an ongoing search for better drugs, but also better carriers. Steroid derivatives, 3β-hydroxy-16-hydroxymino-androst-5-
en-17-one (A) and 3β,17β-dihydroxy-16-hydroxymino-androst-5-ene (B) as cancer growth inhibitors were chemically 
synthesized and captured in a carrier composed of hydroxyapatite (HAp) nanoparticles coated with chitosan 
oligosaccharide lactate (ChOLS). The only difference between the two derivatives is that A has a carbonyl group at the C17 
position of the five-membered ring and B has a hydroxyl. This small difference in the structure resulted not only in 
different physicochemical properties of the A- and B-loaded HAp/ChOSL, but also in different biological activities. The 
morphology of drug-loaded HAp/ChOSL particles was spherical, but the size depended on the drug identity: d50=138 nm 
for A-loaded HAp/ChOSL and d50=223 nm for B-loaded HAp/ChOSL. Cell-selective toxicity was tested against human breast 
carcinoma (MCF7 and MDA-MB-231), human lung carcinoma (A549) and human lung fibroblasts (MRC-5). The small 
selectivity of pure derivatives A and B toward breast cancer cells became drastically increased when they were delivered 
using HAp/ChOSL particles. Whereas the ratio of the cytotoxicity imposed onto breast cancer cells and the cytotoxicity 
imposed onto healthy MRC-5 fibroblasts ranged from 1.5 to 1.7 for pure A and from 1.5 to 2.3 for pure derivative B 
depending on the concentration, it increased to 5.4 for A-loaded HAp/ChOSL and 5.1 for B-loaded HAp/ChOSL. FACS 
analysis demonstrated poor uptake of HAp/ChOSL particles by MCF7 cells, suggesting that the drug release occurs 
extracellularly. The augmented activity of the drugs was most likely due to sustained release, although the favorable 
positive charge of the carrier, allowing it to adhere to the negatively charged plasma membrane and release the drugs 
steadily and directly to the hydrophobic cell membrane milieu, was delineated as a possible complementary mechanism.
Introduction 
Calcium phosphates (CP) were discovered in 17691, almost 250 
years ago, yet today they still present a major research challenge to 
many research groups around the world.2 Synthetic hydroxyapatite 
(HAp), similar in structure to human bone CP, has seen a variety of 
applications in bone tissue engineering due to its excellent 
biocompatibility.3 In addition to its use in reconstructive medicine, 
HAp has increasingly been used as an agent for various therapeutic 
approaches, including chemotherapy, gene therapy, hyperthermia 
therapy, photodynamic therapy, radiation therapy, or combination 
therapy, and even imaging-guided therapy.4 Synthesis and design of 
nanoparticulate HAp for use in medicine and pharmacy as a carrier 
of various drugs and genes is a special field of research.5 Recent 
studies have shown that rod-shaped HAp nanoparticles can produce 
a specific cytotoxic response in lung cancer cells and inhibit their 
proliferation.6 Functional systems based on HAp and polymers allow 
for the tailoring of various physicochemical properties of the 
materials and thus for their more specific and personalized 
applications in medicine.7,8 Biocompatible and bioresorbable 
polymers capable of entrapping drugs of various sizes and 
hydrophobicity have been used to coat nano-HAp and create 
multifunctional systems suitable for reconstruction of bone defects 
with simultaneous controlled drug delivery. 9-12 
Chitins are polysaccharides found in the exoskeleton of certain 
marine crustaceans such as crabs, shrimps, etc. Due to their 
biocompatible, antimicrobial, nontoxic and antitumor properties, 
they are suitable for use in medicine and pharmacy.13 Chitosan (Ch) 
is obtained by deacetylation of chitin in a process that is 
indispensably incomplete.14 In our earlier research we fabricated 
particles composed of nano-HAp coated with either chitosan or Ch-
PLGA polymer blend (HAp/Ch, HAp/Ch-PLGA) suitable as drug 
carriers for intravenous administration.15 After injection into a 
blood vessel, HAp/Ch particles accumulated in the spleen and liver, 
while HAp/Ch-PLGA particles accumulated in the lung.16 Following 
reconstruction of bone defects with HAp/Ch and HAp/Ch-PLGA 
particle systems, their antimicrobial and osteoconductive 
properties were confirmed, along with regeneration of boney 
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tissues.17 Nanocarriers based on PLGA and Ch have been assessed 
as promising in the delivery of various antitumor drugs, as well as 
for straightaway use in the clinical practice.18 Composite particles 
made of Ch and PLGA combine the properties of these two sole 
polymers, which can contribute to improved encapsulation and 
efficacy of encapsulated anticancer drugs.19 Core-shell particles 
comprising Ch shells and PLGA cores were found to be suitable for 
dual drug-loading, as in the cases where simple mixing of two drugs 
without a carrier in combination therapies is ineffectual because of 
a disparity in solubility or pharmacokinetic half-lives. This type of 
core-shell particles can potentially be used as nanovehicles that 
allow for a simultaneous chemotherapy and radiation sensitization 
in lung cancer treatments.20 
Shorter derivatives of chitosan, chitosan oligosaccharides (ChOS) 
generally have inert or anti-inflammatory properties and in certain 
biological interactions can have more favorable properties than 
Ch.21,22 ChOS has shown a high potential for use in a variety of 
biomedical therapies, including immunostimulation, antitumor, 
anti-obesity, anti-hypertension, anti-Alzheimer's disease, tissue 
regeneration promotion, drug and DNA delivery enhancement, 
antimicrobial, anti-oxidation and calcium-absorption 
enhancement.21,23 By coating and functionalizing the surface of the 
Pd particle with ChOS with the aid of surface amines and hydroxyl 
groups of the polymer, a system for active targeting of breast 
cancer cells was obtained with a high percentage of cellular 
uptake.24 In order to reduce the toxic effects and enable specific 
targeting of lung tumor cells, core-shell layer-by-layer particle 
systems have been designed, containing calcium phosphate and 
chitosan oligosaccharide lactate (ChOSL) in which cisplatin was 
incorporated.25 Carriers based on chitosan grafted with oligo(lactic 
acid) were also effective as transdermal drug delivery systems.26 
A wide range of synthetic steroidal heterocyclic derivatives with 
five- and six-membered rings have been found feasible for use in 
the treatment of hormone-dependent cancers. Synthesized from 
medicinal plants, these heterocyclic derivatives proved to be 
promising compounds for stopping the uncontrolled proliferation of 
cancerous cells.27 The molecular mechanism of the anticancer 
activity of this group of derivatives is mainly based on the inhibition 
of the aromatase and sulfatase enzymes.28 An androstan derivative 
with a six-membered ring and a five-membered ring (3-pyridinyl; 
androsta-5,16-dien-3β-ol acetate) is metabolized into products that 
have enabled fine tuning of a prostate cancer therapy during clinical 
trials.
29
 Recent research pointed at the antiproliferative potential of 
modified D-homo lactone androstane derivatives synthesized in our 
laboratory.30,31 HAp/Ch-PLGA particles loaded with an androstane-
based cancer inhibitor (17β-hydroxy-17α-picolyl-androst-5-ene-3β-
yl-acetate) also showed high anticancer activity towards lung cancer 
cells with a simultaneously low toxicity towards healthy cells.32  
In this study we report on the synthesis and characterization of 
spherical particles of a hybrid system made of nano-HAp particles 
coated with chitosan oligosaccharide lactate (ChOSL) and loaded 
with two different, but similar androstane derivatives: 3β-hydroxy-
16-hydroxymino-androst-5-ene-17-one (A), C19H27NO3, and 3β, 17β-
dihydroxy-16-hydroxymino-androst-5-ene (B), C19H29NO3. The 
difference between A and B is that at the C17 position of the five-
membered cyclic ring, A has a carbonyl group (> C = O), whereas B 
has an -OH group (C-17 configuration). Correlation between the 
chemical structure and biological efficiency of the derivatives, 
which is significant for their selective action, has not been fully 
investigated in the literature.21 The results of such studies would 
contribute to the said field. Here we first used 1H and 13C NMR to 
determine the structure of the synthesized derivatives A and B, 
while the content of the derivatives in the HAp/ChOSL particles was 
determined directly using differential scanning calorimetry (DSC). 
Particle morphology was analyzed by atomic force microscope 
(AFM) and the drug loading process was analyzed by simultaneous 
thermogravimetric/differential thermal analyses (TGDTA). 
Electrokinetic particle parameters as potential indicators of the 
activity at the interface between the double charge layer and the 
biological environment were determined by measuring ξ-potential, 
electrophoretic mobility and conductivity. The selective viability 
effect of the androstane-based cancer inhibitors A and B and hybrid 
particles encapsulating them was examined using dye exclusion 
(DET) and MTT assays on the following cell lines: human breast 
carcinoma (MCF-7, MDA-MB-231), human lung carcinoma (A549) 
and human lung fibroblasts (MRC-5).  
 
Experimental 
Synthesis of 3β-hydroxy-16-hydroxymino-androst-5-en-17-on and 
3β,17β-dihydroxy-16-hydroxymino-androst-5-en -loaded 
HAp/ChOL 
Synthesis of 3β-hydroxy-16-hydroxymino-androst-5-en-17-on (A), 
C19H27NO3 and 3β,17β-dihydroxy-16-hydroxymino-androst-5-en 
(B), C19H29NO3 
Mixture of dehydroepiandrosterone (1.00 g, 3.47 mmol), 
potassium tert-butoxide (0.88 g, 7.84 mmol) and freshly prepared i-
amyl nitrite (1.1 mL, 8.07 mmol) in tert-butanol was stirred at room 
temperature for 24 h. When the reaction was complete, the 
mixture was poured into water (100 mL). Acidification with HCl (1:1) 
to pH 6 gave 1.06 g of white powder (99%) of compound A. 
Reduction of compound B (1.06 g, 3.34 mmol) was conducted in 
95% ethanol (60 mL) with sodium borohydride (0.26 g, 6.87 mmol). 
Reaction mixture was stirred at room temperature for 90 min. 
When the reaction was complete, the mixture was poured into 
water (150 mL), acidified with HCl (1:1) to pH 5 and the pure white 
powder of compound B (0.93 g, 86%) were obtained. 
Synthesis of HAp and A(B) loaded HAp/ChOSL  
An aqueous calcium nitrate (Ca(NO3)2) solution (150 ml; 26.6 wt.%) 
was added to the solution of ammonium phosphate ((NH4)3PO4) (7 
ml H3PO4+165 ml NH4OH+228 ml H2O) at 50°C over the period of 60 
minutes, while stirring at the rate of 100 rpm. The solution was 
then subjected to a heat treatment at 100°C for 60 minutes. The 
resulting gel was dried at room temperature in a vacuum drier for 
72 h, after which the final product - HAp powder - was obtained. X-
ray diffraction run on the HAp powder confirmed its poorly 
crystalline nature, whereas the PSD technique enabled us to 
determine the particle size of d50=65 nm.
9 
Chitosan oligosaccharide lactate, (ChOSL), (C12H24N2O9)n, 
(Sigma-Aldrich, Mn=4,000 - 6,000, deacetylation>90%), dissolved in 
acetic acid (1 wt.%), was mixed with C19H27NO3 (A) or C19H29NO3 (B) 
and HAp in the weight ratio of HAp:ChOL:A(B)=5:4:1, while stirring 
with a magnetic stirrer at 400 rpm. The obtained mixture of A (or 
B), ChOL and HAp was slowly poured into a sodium citrate solution 
(0.1 wt.% in H2O) while stirring at 21,000 rpm for 30 min. A water 
solution of poloxamer 188 (polyethylenepolypropylene glycol, 
0.1vol.%) was added dropwise to the resulting mixture, while 
stirring at 21,000 rpm. The obtained mixture was then centrifuged 
at 3000 rpm and 5°C for 1 h, and the resulting precipitate was 
subjected to lyophilization at temperatures ranging from -10 to -
60°C and pressures ranging from 0.37 mbar to 0.1 mbar for 1 to 8 
h.26 The obtained powder was washed with distilled water three 
times, centrifuged at 1000 rpm and dried again. The final product 
was the powder composed of HAp particles coated with A(or B)-
loaded chitosan oligosaccharide lactate (A(or B)-HAp/ChOSL).  
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Characterization of the products 
NMR spectra were recorded on a Bruker AVANCE III HD 400 
spectrometer operated at 400 MHz (1H) and 100 MHz (13C), and 
residual solvent signals were used for the chemical shift (ppm; δ-
scale) calibration. Infrared spectroscopy (FT-IR) was done on a 
Nicolet iS10 FT-IR Spectrometer (Thermo Scientific Instruments) 
in the spectral range from 400 to 4000 cm−1. Differential scanning 
calorimetry (DSC) measurements were performed on an Evo 131 
(Setaram Instrumentation) differential scanning calorimeter. 
Samples containing 5 mg were analyzed in nitrogen by heating 
(10°C/min) from 25°C to 360°C. Thermal analyses were 
simultaneously performed using a Thermo-Gravimetric 
Analysis/Differential-Thermal Analysis (TGA/DTA), SETSYS 2400 CS 
Evolution (Setaram Instrumentation) coupled to a mass 
spectrometric (MS) gas analysis system (Omni Star, Pfeiffer). 
Samples containing about 10 mg were analyzed in air by heating 
(10°C/min) from 28°C to 600°C. Quantitative analysis of the content 
of A and B in A/B-HAp/ChOSL was performed on an Ultimate 3000 
HPLC device equipped with a DAD (Thermo Fisher Scientific, 
Woltham, USA). The separation was carried out in a XBridge C18 
column (100 mm × 4.6 mm, 3.5 μm) from Waters (Milford, USA). 
The mobile phase was composed of water and the organic solvent 
(methanol for A and acetonitrile for B). The detection of products 
was carried out on a UV detector at 230 nm. The HPLC analysis was 
done in triplicates. Electrokinetic parameters of the aqueous 
suspensions of synthesized particles were analyzed using a Zeta-
Sizer Nano (Malvern Instruments Ltd.) in deionized water and pH 
7.0. The particle size distribution (PSD) was measured on 10 mg/ml 
of powders dispersed in water using a Mastersizer 2000 (Malvern 
Instruments Ltd.) and a HydroS dispersion unit for liquid 
dispersants. Microstructural characterization was performed using 
an atomic force microscope (AFM, Thermo Microscopes, Autoprobe 
CP Research). 
Drug Release 
The release rate of steroids A and B in vitro in phosphate buffered 
saline (PBS) at 37oC and in the presence of 0.1 wt.% sodium lauryl 
sulfate (SLS) was studied using HPLC technique. To estimate the 
concentration of the released steroids (A and B) at different time 
points, 50 mg of A-HAp/ChOSL and B-HAp/ChOSL were suspended 
in 50 ml PBS and aliquoted solutions were analyzed in triplicates on 
an Ultimate 3000 HPLC equipped with a DAD (Thermo Fisher 
Scientific, Woltham, USA). The separation was carried out in a 
XBridge C18 column (100 mm × 4.6 mm, 3.5 μm) from Waters 
(Milford, USA). The mobile phase was composed of water and the 
organic solvent (methanol for A and acetonitrile for B). The analysis 
was conducted by gradient elution in the following way: 0-5 min 20 
% of the organic solvent, 5-25 min 20-100% gradient of the organic 
solvent. A flow rate of 0.5 ml/min was used and the column 
temperature was kept at 30oC. The detection of A and B was carried 
out using a UV detector at 230 nm. Concentrations of steroids A 
and B in PBS were calculated using the following equation: CA 
(B)(%)=[(Asteroid  x Vstandard  x Cstandard)/(Astandard x Vsteroid x Csteroid)] x 100, 
where Asteroid and Astandard (mAU*min) is the area of the released 
steroid in HPLC chromatograms, Vsteroid and Vstandard are injection 
volumes of steroid and standard (100%, pure steroid) solutions, 
respectively, and Csteroid and Cstandard are concentrations of steroid 
and standard solutions, respectively. 
 
Biological assays 
Cell lines and cultures 
Study of particle cytotoxicity was carried out on four cell lines: 
human breast carcinoma ER + (MCF-7 ATCC HTB-22), human breast 
carcinoma ER- (MDA-MB-231 ATCC HTB-26), human lung carcinoma 
(A549 ATCC CCL 185) and human lung fibroblasts (MRC-5 ATCC CCL 
171). All cells grew attached to the plate (Costar, 25 ml) in 
Dulbecco's modified Eagle's medium (DMEM, Sigma) with 4.5g/l 
glucose and 10% FCS (fetal calf serum, Sigma). The medium 
contained an antibiotic/antimycotic solution (Sigma). The cell lines 
were maintained under standard conditions: at a temperature of 
37°C in a humidity saturated atmosphere with 5% CO2 (Heraeus). 
Cells were passaged twice a week, and in the experiments the cells 
were used in the logarithmic growth phase between the third and 
the tenth passage. Only viable cells were used. The number of cells 
and their viability were determined by the dye exclusion test with 
0.1% trypan blue. 
Substances tested and the treatment 
Cells were harvested in the logarithmic growth stage, precipitated 
by centrifugation (10 min/200 x g) and counted in 0.1% trypan blue. 
Particles were compressed into discs and placed at the bottom of 
Petri dishes (Center well, Falcon) seeded with viable cells. Each disc 
contained 50 mg of the powder and was immersed in 5 ml of cell 
culture media. The control samples did not contain any particles. 
The Petri dishes with seeded cells were left in a thermostat at 37°C, 
with 5% CO2 for 48h. 
DET - Dye exclusion test 
After the incubation, the cells were separated from particles by 
tripsinization (adding 0.1% solution of tripsin). The cell number and 
viability were measured using a trypan blue dye exclusion test 
(DET). Exponentially growing cells were harvested and counted by 
DET. Cell counting was performed following the incubation, using 
an inverted microscope (REICHERT) in counting chambers. Viability 
was calculated as V = (Nv/Nt) x 100, where Nv is the number of 
viable cells, and Nt is the total number of cells in the sample. The 
wells containing cells without tested substances were used as 
control. Cytotoxicity (CI) obtained in the DET was expressed as a 
percentage according to the formula: CI = (1-Ns/Nk) x 100, where Nk 
is the number of cells in the control sample, and Ns is the number of 
cells in the sample with the tested substance. 
MTT - Colorimetric Test with Tetrazolium Salt 
After the DET, cytotoxicity was investigated from the aspect of cell 
recovery using the MTT assay. The viable cells were seeded 
(5×103/100μl) in quadruplicate in 96-well microtiter plates. The 
plates with seeded cells were left in a thermostat at 370C, with 5% 
CO2 for 48h and 72h. Freshly prepared MTT solution was added to 
the wells at 10 μl/well and incubation was continued for 3 hours (in 
a 370C thermostat with 5% CO2). After 3h, 100 μl of 0.04 mol/l HCl 
in isopropanol was added to each well. Absorbance was read 
immediately after the incubation period on the microtiter plate 
reader (Multiscan Ascent, Thermo Labsystems) at the wavelength of 
540 nm and a reference of 690 nm. The wells containing only the 
medium and MTT, but not the cells, were used as a blank.33 
Cytotoxicity (CI) was expressed as a percentage according to the 
formula: CI = (1-As/Ak) x 100, where Ak is the absorbance of the 
control sample, and As is the absorbance of the samples with the 
tested particles. 
Fluorescent cell imaging  
MCF-7 cells were fixed and stained for nuclei, f-actin filaments and 
HAp/ChOSL, A-HAp/ChOSL and B-HAp/ChOSL particles 24 hours 
after adding the particles to the culture at the concentration of 5 
mg/ml. Cells were fixed for 5 minutes in 4 % paraformaldehyde 
(PFA) and washed 3 x 10 min in PBS, then blocked at room 
temperature for 1 h in the blocking solution (2 % bovine serum 
albumin, 0.5 % Triton-X in PBS), washed 3 x 10 min with PBS again 
and stained with Alexa Fluor 568 phalloidin (1:400) and NucBlue® 
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Fixed Cell ReadyProbesTM reagent (Molecular Probes, Life 
Technologies) for 1 hour at room temperature. HAp/ChOSL particles 
exhibited intrinsic fluorescence and needed not be stained with a 
dye. After the incubation, the cells were washed 3 x 5 min with PBS 
and mounted using Prolong Diamond mounting media (Life 
Technologies). Images were acquired on a Nikon T1-S/L100 inverted 
epifluorescent confocal microscope. All the samples were analyzed 
in triplicates. 
Flow cytometry 
In addition to fluorescent cell staining, the uptake of pure and drug-
loaded HAp/ChOSL particles by MCF-7 cells was analyzed using 
fluorescence activated cell sorting (FACS, Becton Dickinson 
FACSVerse). MCF-7 cells were grown to confluency in 
aforementioned growth conditions in 24 well plates before 5 mg/ml 
of the nanoparticles were added to them. After 24 h incubation at 
37 oC, the cells were rinsed with PBS and trypsinized using 0.25 % 
trypsin-ethylenediaminetetraacetic acid (EDTA). The cells that had 
uptaken the nanoparticles were sorted from the untreated, control 
cells based on changes in the increased side scatter (SSC) indicative 
of increased granularity in the cells due to intracellular localization 
of nanoparticles uptaken by the cells. All the samples were analyzed 
in triplicates. 
 
Results and discussion 
Figure 1 shows the structures (Figs. 1a, b) and 1H, 13C spectra of 
compounds A and B. Compound A (Fig. 1c): 1H NMR (DMSO-d6, δ, 
ppm): 0.87 (s, 3H, H-18), 0.99 (s, 3H, H-19), 2.72 (dd, J = 17.3, 6.8 
Hz, 1H, H-15), 3.26 (ddd, J = 15.2, 10.2, 5.1 Hz, 1H, H-3), 4.63 (d, J = 
4.4 Hz, 1H, 3β-OH), 5.31 (d, J = 4.8 Hz, 1H, H-6), 12.35 (s, 1H, NOH). 
13C NMR (DMSO-d6, δ, ppm): 14.10 (C-18), 19.62 (C-19), 20.28, 
25.76, 30.44, 30.79, 31.17, 31.85, 36.72, 37.22, 42.66, 46.18, 48.42, 
49.96, 70.42 (C-3), 120.38 (C-6), 141.93 (C-5), 155.90 (C-16), 205.33 
(C-17).  
Compound B (Fig. 1d): 1H NMR (DMSO-d6, δ, ppm): 0.62 (s, 3H, 
H-18), 0.96 (s, 4H, H-19), 2.31 (dd, J = 17.8, 7.4 Hz, 1H, H-15), 3.27 
(ddd, J = 15.6, 10.8, 4.7 Hz, 1H, H-3), 3.87 (dd, J = 5.7, 1.9 Hz, 1H, H-
17), 4.62 (d, J = 4.5 Hz, 1H, 3β-OH), 4.93 (d, J = 5.8 Hz, 1H, 17β-OH), 
5.28 (d, J = 5.0 Hz, 1H, H-6), 10.38 (s, 1H, NOH). 13C NMR (DMSO-d6, 
δ, ppm): 11.82 (C-18), 19.63 (C-19), 20.67, 27.26, 31.16, 31.32, 
31.87, 36.18, 36.68, 37.31, 42.68, 43.16, 46.59, 50.22, 70.45 (C-3), 
81.06 (C-17), 120.64 (C-6), 141.83 (C-5), 162.73 (C-16). 
Dehydroepiandrosterone was converted into the corresponding 
16-oximino derivative (A, Fig 1a). In the earlier synthetic procedure, 
potassium tert-butoxide was obtained in the reaction of potassium 
with tert-butanol.34 Commercially available potassium tert-butoxide 
was used here instead. Structure A was confirmed in the 1H (Fig. 1c) 
and 13C NMR spectral analysis (Fig.1e). In these spectra, the key 
signals for structure determination were the oximino proton singlet 
at 12.35 ppm and the carbonyl C-16 signal at 155.90 ppm. 
Compound B (Fig. 1b) was obtained by the reduction of C-17 
carbonyl group of compound A. Structure B was confirmed by the 
17β-OH proton signal at 4.93 ppm and the oximino proton singlet at 
10.38 ppm in the 1H NMR spectrum (Fig. 1d) and the signal of C17 in 
the 13C NMR spectrum (Fig. 1f), which is shifted up field compared 
to the same proton of compound A ( 205.33 for A1  81.06 for B). 
 
 
 
 
 
 
Figure 1. Structures and 1H, 13C spectra of compounds A and B: a) 
structure of A, b) structure of B, c) 1H NMR of A, d) 1H NMR of B,  e) 
13C NMR of A, f) 13C NMR of B 
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Figure 2 shows the IR spectra of HAp, ChOSL, A, A loaded 
HAp/ChOSL, B and B loaded HAp/ChOSL. The characteristic bands at 
about 1030 cm-1 and 1080 cm-1 could be assigned to the triply 
degenerated asymmetric stretching vibration mode (ν3) of the PO4
3- 
group of HAp and the band at 3560 cm-1 to the stretching vibration 
of the OH- group (Figure 2a). The absorption band at about 563 cm-1 
was assigned to the triply degenerated bending mode (ν4) of the 
PO4
3- group.35,36 Vibration of the hydroxyl group characteristic of 
ChOSL, detected at  3650 cm-1 (Figure 2b), has been confirmed by 
other authors.37 C-H symmetric stretching vibrations of CH2 at 
about 2880 cm-1 as well as C-O-C stretching vibrations at about 
1070 cm-1 are clearly visible too.38 Vibrations at roughly 1560 and 
1400 cm-1, characteristic for the amide groups of ChOSL, were also 
recorded.37 The most pronounced, sharp band in the spectrum of 
derivative A (Figure 2c) at 1731 cm -1 originates from the vibration 
of the C17 carbonyl group. In the spectrum of A-loaded HAp/ChOSL 
(Fig. 2d), the characteristic bands of derivative A are observed in 
addition to those of HAp and ChOSL. A characteristic series of 
several sharp bands in the spectrum of derivative B (Figure 2e) at 
2934, 2891 and 2853 cm-1 is attributed to C-H vibrations from the 
steroid skeleton. These bands are also present in the B-HAp/ChOSL 
spectrum (Figure 2f) in addition to the characteristic bands of HAp 
and ChOLS. The presence of the characteristic bands of pure 
derivatives A and B (Figs 2c, e) in A-HAp/ChOSL and B-HAp/ChOSL 
systems (Figs 2d, f), respectively, could indicate that derivatives A 
and B during the synthesis procedure were entrapped in the ChOSL 
polymer.  
The results of the TG-DT analyses of HAp, ChOSL, A, A-
HAp/ChOSL, B and B-HAp/ChOSL in the 30-600°C temperature 
range are shown in Fig. 3. The TGA curve of HAp showed a residue 
of 93±0.5% at 600°C (Figure 3a). At the same temperature (600°C), 
the residue originating from ChOSL was only 8±0.5% (Figure 3b). 
The moderate weight loss of the derivatives and derivative loaded 
particles (Fig. 3c, d, e, f) up to about 220°C is associated with the 
loss of adsorbed water. The TGA curves of A (Fig. 3c) and B (Fig. 3e) 
show complete degradation at 600°C (100% mass loss). Albeit 
similar in structure (Figs 1a, d), derivatives A and B behaved 
differently in the thermal degradation mode (Figs 3c, e). Namely, 
derivative A achieved the weight loss of 50% at the temperature of 
372°C, as opposed to derivative B, whose weight loss of 50% was 
recorded at 412°C. The complete thermal decomposition of 
derivative A (Figure 3c) was marked by a broad exothermic peak of 
the DTA curve in the 480-590°C range. Decomposition of derivative 
B (Figure 3e) was, in contrast, marked by two exothermic peaks in 
the 480-540°C and 540-590°C intervals, which could indicate a 
vastly different mechanism of thermal degradation caused by the 
rather small difference in the structure. A wide exothermic peak in 
the 250-400°C interval was the signature one in the DTA curves of 
both A-HAp/ChOSL and B-HAp/ChOSL (Figs 3d, f) and it originated 
from the thermal degradation of ChOSL. It could be assumed that as 
the temperature increases, interactions occur between the 
oligosaccharide fragments, leading to formation of new molecules, 
especially at higher temperatures.39 The TGA curves for both A-
HAp/ChOLS and B-HAp/ChOLS determined a residue of 49.0±0.5% 
at 600°C. Based on the amount of this residue, the fraction of HAp 
(experimental sections; HAp: ChOSL:A or B = 5:4:1) in the composite 
systems, equal to 50 wt.%, was confirmed in both of the drug-
loaded systems [HAp(50wt.%x0.93)+ChOLS(40wt.%x0.08)+(A or 
B)(10wt.%x0)=49.7wt.%49.0±0.5%].  
 
 
 
Figre 2. ATR FTIR spectra of: a) HAp, b) ChOSL, c)A, d) A-loaded 
HAp/ChOSL, e) B and f) B-loaded HAp/ChOSL. 
 
 
Figure 3. TGA/DTA diagrams of a) HAp, b) ChOSL, c) A, d) A-loaded 
HAp/ChOSL, e) B and f) B-loaded HAp/ChOSL. 
 
The DSC thermograms of ChOSL, A, A-HAp/ChOSL, B and B-
HAp/ChOSL are shown in Figure 4. The wide endothermic peak 
centered at 107oC originates from the loss of water and represents 
the energy needed for the water to evaporate.40 The endothermic 
phase transition dominates the DSC thermogram of ChOSL with a 
sharp peak centered at 227.4°C (Figure 4a), originating from the 
melting of ChOSL with the collapse of its structure.41 The sharp 
exothermic peak centered at 240.5°C dominates the DSC 
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thermogram of derivative A (Fig.4b) and is also observed on the DSC 
thermogram of A-HAp/ChOSL, albeit centered at 236.3oC. This shift 
to a lower temperature can be attributed to the formation of 
hydrogen bonds between ChOSL and the drug42, in this case 
derivative A, which makes the derivative more susceptible to heat. 
The DSC thermogram of derivative B (Figure 4c), alongside the wide 
endothermic peak centered at 95°C (onset: 72oC, offset: 104oC), 
features a complex exothermic phase transition centered at 189oC. 
The exothermic phase transition of derivative B centered at 202oC is 
also recognized in the DSC thermogram of B-HAp/ChOSL (Figure 
4d). In the thermograms of A-HAp/ChOSL and B-HAp/ChOSL (Figs 
4c, e), the melting endotherm of pure ChOSL (Figure 4a) is not 
present, which suggests that introducing HAp and the derivatives 
significantly improves the heat stability of ChOSL. Similar 
improvements in the thermal stability of chitosan derivatives upon 
the addition of inorganic components has been evidenced in DSC 
analyses by other authors too.41 Differential scanning calorimetry 
(DSC) is a technique suitable for the prediction of the drug loading 
efficiency of poorly water-soluble compounds in pharmaceutical 
preparations based on measuring phase transition enthalpy.43 
Derivatives A and B belong to one such group of poorly water-
soluble compounds. By integrating over the surface of the 
exothermic peaks of the characteristic phase transitions of pure 
(100%) and encapsulated derivatives A and B, we obtained the 
enthalpy values (ΔH) shown in Table 1. By comparing the enthalpies 
of pure and encapsulated derivatives A and B, the content of the 
encapsulated derivative A in A-HAp/ChOSL and B in B-HAp/ChOSL 
was derived and it equaled is 8.9±0.1wt.% and 9.0±0.1wt.%, 
respectively. 
Steroids A and B were extracted from carriers using 
MeOH:CH2Cl2 (1:1). The content of A and B in A-HAp/ChOSL and B-
HAp/ChOSL was also confirmed using HPLC. By comparing the areas 
of typical chromatogram peaks of pure and extracted steroids A 
(retention time 17 min) and B (retention time 27 min), the content 
of the encapsulated steroids A in A-HAp/ChOSL and B in B-
HAp/ChOSL were derived and equalled 9.0±0.1 wt.% and 9.1±0.1 
wt.%, respectively (mean ± SD), being in excellent agreement with 
the values obtained from DSC measurements. 
 
 
Figure 4. DSC thermograms of: a) ChOSL, b) A, c) A-loaded 
HAp/ChOSL, d) B and e) B-loaded HAp/ChOSL. 
 
Table 1. Enthalpies and the content of A and B in the drug-loaded 
HAp/ChOSL according to the DSC results. Results are presented as 
means ± standard deviation (SD). 
Name Enthalpy, H of encapsulated 
A/B [Jg-1] 
The content of the 
encapsulated A/B 
[wt.%] 
A, pure -447.2 100 
B, pure -229.3 100 
A-HAp/ChOSL -39.8±0.3 8.9±0.1 
B-HAp/ChOSL -20.6±0.2 9.0±0.1 
Numerous factors influence the interactions between particles 
and the biological environment along the bio-nano interface44 and 
size, shape, surface chemistry, particle texture and topography are 
only some of them. Electrokinetic parameters are important not 
only in the prediction of particle-particle interactions, but also for 
the interaction of particles with the cell surface. Table 2 shows the 
values of ξ-potential and electrophoretic mobility of drug-free 
HAp/ChOSL, A-HAp/ChOSL and B-HAp/ChOSL particles and of the 
conductivity of their suspensions. Because of the partial 
protonation of C2 amino groups (pKa ~ 6.5) at the neutral pH, Ch 
and its derivatives carry a net positive charge under physiological 
conditions, explaining the positive ξ-potential value of 13.8 ± 0.82 
mV for HAp/ChOLS and indirectly confirming that HAp is coated by 
ChOSL. By introducing a drug derivative into the HAp/ChOSL carrier, 
the value of ξ-potential changes from 13.8 ± 0.82 mV for the drug-
free carrier to 30.3 ± 0.26 mV for A-HAp/ChOLS particles and 32.3 ± 
0.67 mV for B-HAp/ChOSL particles. Both of the drug-loaded 
particles in suspension present ξ-potential values that exceed the 
stability threshold45 of 30 mV, suggesting that theirs are stable 
colloidal systems suitable for intravenous delivery. The 
electrophoretic mobility of the particles and the conductivity of the 
medium containing the dispersed particles reflect the somewhat 
higher ξ-potential values detected for B-HAp/ChOSL, being also 
higher for this system (Table 2) compared to A-HAp/ChOLS 
particles. Although this difference was small, it was still statistically 
significant (p < 0.01). It is conceivable that either the small 
difference in the dissociation of the two derivatives or the 
somewhat more electrophilic character of the C-17 carbonyl than 
the hydroxyl affects the content of the surface groups and, thus, the 
ionic makeup of the double charge layer, which is further being 
reflected in the different specific and nonspecific ion effects46 that 
govern the particle/cell interaction. There are indications that 
healthy cells have a different surface charge and ξ-potential 
compared to cancer cells47  and since the first step in the interaction 
of the particles and the cells occurs at the electrostatic level, the 
possibility that the two synthesized systems would  interact 
differently with healthy and cancer cells or with cells in general 
cannot be discarded. These phenomena were investigated in in 
vitro tests.  
 
Table 2. Zeta potential, electrophoretic mobility and sol 
conductivity of HAp/ChOSL, A-HAp/ChOSL and B-HAp/ChOSL 
particles (ξ—zeta potential; µe—mobility; -conductivity) 
Name Temperature 
[°C] 
ξ 
[mV] 
ue 
[x10-8 m2V-1s-1] 
  
[mScm-1] 
HAp/ChOSL 25 13.80±0.82* 1.10±0.01* 0.050±0.002* 
A-HAp/ChOSL 25 30.30±0.26* 2.40±0.04* 0.460±0.011* 
B-HAp/ChOSL 25 32.30±0.67* 2.50±0.05* 0.550±0.014* 
*SD 
 
Molecular polar surface area (PSA), i.e., the portion of the 
molecular surface occupied by polar atoms, is a descriptor that 
allows the prediction of the drug transport properties. Topological 
PSA (TPSA) represents the sum of the surfaces of polar atoms and 
groups in the molecule.48 Based on the methodology detailed in the 
literature48, TPSA values were calculated for derivatives A and B, 
and these were A=69.89Å2 and B=73.05Å2, respectively. Based on 
the obtained results, it can be noticed that derivative B is little more 
polar (5%) than derivative A, so that a difference can be expected in 
the activity in the bio-nano interface with identical cells. 
Hydrodynamic particle size distribution (PSD) histograms and 
surface morphologies of A-HAp/ChOSL and B-HAp/ChOSL particles 
analyzed using laser diffraction and AFM in the non-contact mode, 
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respectively, are shown in Figure 5. A-HAp/ChOLS particles had a 
uniform distribution of sizes, with the d50 parameter being equal to 
138 nm. The powder contained small portions of larger and smaller 
particles; correspondingly, d90=227 nm and d10=115 nm. B-
HAp/ChOSL particles had the following distribution values: d10 =172 
nm, d50=223 nm and d90=443 nm. A portion of larger particles (d90 = 
443 nm) is the most likely the product of agglomeration, which can 
be seen in Fig. 5b. Overall, the given laser diffraction values indicate 
a larger particle size for B-loaded HAp/ChOSL than for A-loaded 
HAp/ChOSL (Figure 5b). Still, as evidenced by AFM analyses, both 
powders contained equally spherical particles. After coating HAp 
with the drug-loaded ChOSL, the particles were processed in a 
centrifugal field (21,000 rpm, experimental sections), implying that 
spherical morphologies were expected. In general, the processing of 
polymer systems in the centrifugal field leads to the formation of 
spherical morphologies of the processed particles.49 
 
 
 
Figure 5. PSD histograms and AFM images of a) A-loaded 
HAp/ChOSL and b) B-loaded HAp/ChOSL. 
 
By comparing the areas of released steroids (A retention time of 
17 min; B retention time of 27 min) in HPLC chromatograms, 
concentrations of the released derivatives were obtained. Figure 6 
shows the percent cumulative release of A and B in PBS at 37 oC 
under static conditions. During an 8-day period, the entire content 
of A and B was released from all the systems. The release followed 
a relatively linear, zero-order kinetic pattern for A and B during the 
first two days. Initially, after the first 24 h of degradation, 42% and 
39% of A and B, respectively were released. Nearly complete 
release of the derivatives A and B, was registered after the third 
day, i.e. 93% and 90% of A and B, respectively.  
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Figure 6. Comparative cumulative curves of the release of A and B 
in percents in PBS at 37oC over the degradation period. 
 
Figure 7 shows the cytotoxicity of healthy and breast cancer 
cells (MCF7 and MDA-MB-231), lung cancer cells (A549) and human 
fibroblasts (MRC-5) after incubation with drug free HAp/ChOLS, A-
HAp/ChOLS and B-HAp/ChOLS, as measured in DET and MTT assays. 
The results of comparative DET testing of HAp/ChOLS, A-
HAp/ChOLS and B-HAp/ChOLS particles for cytotoxicity towards 
MRC5, A549, MCF7 and MDA-MB-231 cells are shown in Figure 7a. 
Drug free HAp/ChOLS particles did not exhibit a significant cytotoxic 
effect (< 5 %) toward any one of the examined cell lines after 48 
hours of incubation. Even at this low, practically negligible range of 
toxicities, the drug-free HAp/ChOLS particles were more viable to 
healthy MRC-5 cells than to cancerous A549. After 48 hours of 
action, B-HAp/ChOLS particles induced a greater cytotoxicity to all 
cancer cell lines tested in comparison with A-HAp/ChOLS. Thus, for 
example, B-HAp/ChOLS particles in the DET assay 48 h into the 
treatment (Figure 7b) maintained a high viability of healthy cells 
(95%), but reduced the viability of breast cancer cells (MDA-MB-
231) down to 28%. The same trend was observed during the MTT 
test (Figure 7c). Three days (72 h) after a two-day treatment (48h) 
of the cells with the particles (Figure 7d), the trend observed with 
respect to healthy and cancer cells after shorter 
incubation/recovery periods still applied, suggesting prolonged 
effects exhibited by B-HAp/ChOLS particles, in this particularly 
against MCF-7 breast cancer cells. After the same time interval, a 
slight recovery of all other cells exposed to A-HAp/ChOLS particles 
was observed (Figure 7b), in particular the healthy MRC-5 cells. In 
general, however, A-HAp/ChOLS and B-HAp/ChOLS particles 
showed negligible inhibitory effects on healthy MRC-5 cells (Figure 
7b). It is possible that the treatment results in the loss of the ability 
to use aerobic respiration due to mitochondrial defects in cancer 
cells, but not in healthy cells too.50 This phenomenon may also be 
one of the reasons for higher endurance of the treated healthy cells 
compared to the breast and lung cancer cells.  
 
  
  
 
Figure 7. Dye exclusion test (DET) and colorimetric tetrazolium salt 
(MTT) assay for different cell types challenged with HAp/ChOSL 
(drug-free), A-loaded HAp/ChOSL and B-loaded HAp/ChOSL 
particles: a) DET cytotoxicity @ 48h, b) DET viability @ 48h, c) MTT 
cytotoxicity @ 48 h + 48 h of recovery d) MTT cytotoxicity @ 48 h + 
72 h of recovery. 
 
Fig.8 shows that the selective activity of the drug-loaded 
HAp/ChOSL particles is significantly higher than that of either A or B 
in their pure form. Specifically, at the dose of 20 nM of the pure 
derivative A, at which the cytotoxicity imposed on healthy MRC-5 
cells by the pure drug equals that imposed by A-HAp/ChOSL 
particles, the cytotoxicity imposed onto breast cancer MCF-7 cells is 
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significantly higher for A-HAp/ChOSL particles than for the pure 
derivative A: 54 vs. 15% (Fig. 8a). Similarly, at the dose of 300 uM of 
the pure derivative A, at which the cytotoxicity imposed on 
cancerous MCF-7 cells by the pure drug equals that imposed by A-
HAp/ChOSL particles, the cytotoxicity imposed onto the healthy 
MRC-5 cells is significantly lower for A-HAp/ChOSL particles than for 
the pure derivative A: 10 vs. 31.5% (Fig.8a). The same trend is 
observed for the derivative B. Namely, at the dose of 100 nM of the 
pure derivative B, at which the cytotoxicity imposed on healthy 
MRC-5 cells by the pure drug equals that imposed by A-HAp/ChOSL 
particles, the cytotoxicity imposed onto breast cancer MCF-7 cells is 
significantly higher for B-HAp/ChOSL particles than for the pure 
derivative B: 71 vs. 32% (Fig. 8b). Similarly, at the dose of 1.3 mM of 
the pure derivative B, at which the cytotoxicity imposed on 
cancerous MCF-7 cells by the pure drug equals that imposed by B-
HAp/ChOLS particles, the cytotoxicity imposed onto the healthy 
MRC-5 cells is significantly lower for B-HAp/ChOSL particles than for 
the pure derivative A: 14 vs. 45% (Fig. 8b). Consequently, the ratio 
of the cytotoxicity imposed onto cancerous MCF-7 cells to the 
cytotoxicity imposed onto healthy MRC-5 cells is significantly higher 
for both A- and B-loaded HAp/ChOSL than for the pure derivatives A 
and B (Fig.8c). These results indicate that the ability to selectively 
target breast cancer cells for destruction while leaving the healthy 
cells negligibly affected is due to the carrier and not the drug. As 
terminological clarification, by targeting here we primarily mean 
the ability of a carrier to affect the viability of one cell type (in this 
case, cancer cells) more than it affects the viability of another cell 
type (in this case, healthy cells), regardless of whether this involves 
a tighter physical interaction with the former cells, such as through 
ligand-receptor attraction, or a purely chemical effect, such as 
through greater susceptibility of the former cells to a chemical 
attack over the latter cells.  
 
 
Figure 8. Comparative cytotoxicity of healthy MRC-5 and breast 
cancer MCF-7 cells following 72 h incubation with different doses of 
pure derivatives A or B and A- or B-loaded HAp/ChOSL particles. (a) 
Cytotoxicity at 20 nM and 300 uM A compared to A-HAp/ChOSL. (b) 
Cytotoxicity at 100 nM and 1.3 mM B compared to B-HAp/ChOSL. 
(c) Ratio of the cytotoxicity imposed onto cancerous MCF-7 cells to 
the cytotoxicity imposed onto healthy MRC-5 cells by pure 
derivatives A or B compared to A-HAp/ChOSL and B-HAp/ChOSL. 
FACS studies have demonstrated that there was a negligible 
uptake of both drug-free and drug-loaded HAp/ChOSL particles by 
MCF7 breast cancer cells. The uptake was definitely present in the 
cells, as evidenced by the statistically significantly higher cell 
granularity in sample groups treated with HAp/ChOSL particles, be 
they drug-free or drug-loaded (Fig.10). However, less than 1% of 
cells in any given population uptook the particles. The pure, drug-
free HAp/ChOSL particles were uptaken by the cells slightly more 
than the two drug-loaded HAp/ChOSL particle formulations, but the 
difference was not statistically significant. Since the viability of this 
same breast cancer cell line was affected by the particle treatment, 
which was mostly due to the derivatives A or B released by the 
particles, this has suggested that the drug release occurs 
extracellularly and that the particles do not assist the drug in 
crossing the plasma membrane. The particles, however, owing to 
their favorable positive charge, may still augment the activity of the 
drug by adhering tightly to the outer surface of the negatively 
charged plasma membrane. Fluorescent imaging of the interface 
between the MCF7 breast cancer cells and the drug-free and drug-
loaded HAp/ChOSL particles has shown that there is indeed some 
level of interaction between the two entities. As seen in Fig. 9, the 
particles do co-localize to some degree with the cell boundaries, 
suggesting that the particles might be able to adhere to the cell 
membrane and release derivatives A and B directly in the vicinity of 
the cell membrane, thus helping it traverse the intrinsically 
unfavourable, hydrophilic milieu of the extracellular medium and be 
released straight into the favourable, hydrophobic cell membrane 
microenvironment. Another, more probable means by which the 
particles could augment the efficacy of the derivatives may be by 
sustained release, which would extend the half-life of the drug and 
prevent its rapid degradation upon administration as a bolus. In 
addition, as seen in Fig.9, control MCF7 cells display a 
characteristically wedged pattern of f-actin microfilaments, 
reflecting the orderly arrangement of the cells in planar monolayers 
of the 2D culture. This pattern is unchanged upon the treatment 
with drug-free HAp/ChOSL particles, but becomes severely 
disrupted upon the treatment with either A- or B-loaded 
HAp/ChOSL particles. In the drug-treated population, certain areas 
shows signs of disrupted cell organization, while others show more 
severe diminishments in the expression of cytoskeletal 
microfilaments (Fig. 9).  
 
Figure 9. Fluorescent optical micrographs of fluorescently stained 
MCF7 breast cancer cells (cytoskeletal f-actin - phalloidin; nucleus - 
DAPI) of the negative control and of cells incubated with 
HAp/ChOSL, A-HAp/ChOSL or B-HAp/ChOSL particles (green) 
following 24 h of incubation.  
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Figure 10. FAC sorting of MCF7 breast cancer cells to determine the 
nanoparticle uptake based on increased granularity in cells, as 
represented by cell populations with an increased side scatter (SSC) 
profile. Parental MCF7 cell population with no particle uptake (a) 
and MCF7 cells treated with HAp/ChOSL (b), A- HAp/ChOSL (c) and 
B- HAp/ChOSL (d) particles showing two populations of cells, the 
parental control and one exhibiting granularity. (e) Percentage of 
cells uptaking HAp/ChOLS, A-HAp/ChOSL and B- HAp/ChOSL 
particles compared to the remaining population. Data points are 
shown as averages (n = 3) with error bars representing the standard 
deviation. Statistically significant difference (p < 0.05) compared to 
the untreated, control population is represented with an asterisk. 
 
Summary 
 
We previously demonstrated the feasibility of using spherical 
composite particles based on nano-HAp coated with chitosan-based 
polymers as a vehicle for parenteral administration of drugs. Here 
we report on the synthesis of a carrier composed of nanoparticulate 
hydroxyapatite (HAp) coated with chitosan oligosaccharide lactate 
(ChOSL). The composite particles were found to be suitable as a 
vehicle for the delivery of steroid derivatives 3β-hydroxy-16-
hydroxymino-androst-5-ene-17-one (A) and 3β, 17β-dihydroxy -16-
hydroxymino-androst-5-ene (B). The two heterocyclic derivatives 
contain three six-membered rings and one five-membered ring 
each and differ only in the fact that the derivative A has a carbonyl 
group (> C = O) at the C17 position of the five-membered ring in 
place an -OH group in the derivative B. 1H NMR and 13C NMR 
confirmed the correct chemical structure of the synthesized 
derivatives A and B introduced into the vehicles made of nano-HAp 
coated with ChOSL (HAp/ChOSL). We employed emulsification and, 
subsequently, lyophilization in the synthesis of HAp/ChOSL carriers 
loaded with derivatives A or B. Simultaneous FT-IR and TG-DT 
analyses confirmed that the drug loading was successful. Although 
the particles of both A-HAp/ChOSL and B-HAp/ChOSL adopted 
spherical morphologies, their sizes differed, equalling d50=138 nm 
and d50=223 nm , respectively, reiterating the significant changes in 
the particle properties resulting from the relatively minor 
modification in the drug structure, namely the conversion of C-17 
carbonyl to hydroxyl. 
The selective anticancer activity of the particles was 
confirmed using DET and MTT assays on the following cell lines: 
human breast carcinoma (MCF7 and MDA-MB-231), human lung 
carcinoma (A549) and human lung fibroblasts (MRC-5). The DET test 
revealed that A-HAp/ChOSL particles exhibit on average fourfold 
cytotoxicity toward breast cancer cells (MDA-MB-231) compared to 
that exhibited toward healthy cells (MRC-5) after 48 hours of 
incubation. Per the results of the MTT assay, B-HAp/ChOSL particles 
produce nearly six times greater cytotoxicity to all the breast cancer 
cell lines than to healthy cells after the 96 h and 120 h treatments. 
Particularly noticeable in the MTT assay were the toxicities imposed 
by A-loaded HAp/ChOSL and B-loaded HAp/ChOSL onto MDA-MB-
231 and MCF7 breast cancer cells, respectively (> 70%), while at the 
same time bearing six times lower toxicity to the healthy MRC-5 
line. After 48 h of treatment with B-loaded HAp/ChOSL particles, 
DET testing showed a similar selectivity, specifically high viability of 
healthy cells (83 %) and low viability of all cancer cell lines, 
particularly the breast (MDA-MB-231, 28 %). The rather limited 
selectivity of pure derivatives A and B toward breast cancer cells 
became drastically increased when they were delivered using 
HAp/ChOSL particles. Thus, whereas the ratio of the cytotoxicity 
imposed onto breast cancer cells and the cytotoxicity imposed onto 
healthy MRC-5 fibroblasts ranged from 1.5 to 1.7 for pure A and 
from 1.5 to 2.3 for pure derivative B depending on the 
concentration, it increased to 5.4 for A-loaded HAp/ChOSL and 5.1 
for B-loaded HAp/ChOSL. In total, A-loaded HAp/ChOSL particles 
imposed 2 – 6 times greater toxicity to cancer cells than to healthy 
cells depending on the cell lines compared and cytotoxicity assays 
used, and this ratio was higher, equalling 4 – 6 times for B-loaded 
HAp/ChOSL. FACS analysis demonstrated poor uptake of 
HAp/ChOSL particles by MCF7 cells, suggesting that the drug release 
occurs extracellularly and the particles do not assist the drug to 
cross the plasma membrane. The augmented activity of the drugs 
by the carrier is most likely due to sustained release, but the 
favourable positive charge of the particles, allowing them to adhere 
to the outer surface of the negatively charged plasma membrane 
and release the drugs steadily and directly to the hydrophobic cell 
membrane milieu is a possible complementary mechanism. In 
support of this mechanism of action, fluorescent imaging of the 
interface between the MCF7 breast cancer cells and the drug-
loaded HAp/ChOSL particles has shown the areas of co-localization 
of the particles with the cell boundaries, in addition to the evident 
regions of disrupted cytoskeletal structure resulting from the 
treatment with A-HAp/ChOSL and B-HAp/ChOSL particles, but not 
drug-free HAp/ChOSL. 
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